Literature DB >> 30829772

No Additional Benefit of Combining Fractional Carbon Dioxide Laser With Narrow-Band Ultraviolet B Phototherapy for Vitiligo: A Randomized Prospective Study With Half-Body Side Comparison.

Pelin Eşme1, Güneş Gür Aksoy2, Gonca Elçin1.   

Abstract

BACKGROUND: Narrow-band ultraviolet B (nb-UVB) phototherapy constitutes the gold standard treatment for vitiligo. Whether carbon dioxide (CO2) laser might increase the efficacy of nb-UVB is still a topic of debate.
OBJECTIVE: To test the hypothesis that the addition of fractional CO2 laser to nb-UVB may enhance repigmentation. PATIENTS AND METHODS: Fractional CO2 laser was applied with an interval of 2 weeks for 7 sessions, only to 1 of the 2 symmetrical vitiligo patches located on 2 different half-body sides. Patients received whole-body nb-UVB phototherapy 3 times a week, for at least 4 months. Repigmentation was scored with a quartile grading scale, with the help of a computer program using the photographs taken by the digital dermatoscope.
RESULTS: Fifty-one symmetrical vitiligo patches of 30 patients were included. No statistically significant difference was found between the mean repigmentation scores for the laser and nonlaser sides (p = .11).
CONCLUSION: Results of this study suggest that combining fractional CO2 laser with nb-UVB phototherapy with the regimen used in this study does not increase the repigmentation scores for vitiligo.

Entities:  

Year:  2019        PMID: 30829772     DOI: 10.1097/DSS.0000000000001890

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  2 in total

1.  The efficacy of fractional carbon dioxide laser combined with narrow-band ultraviolet B phototherapy for non-segmental vitiligo: a systematic review and meta-analysis.

Authors:  Woo Il Kim; Sooyoung Kim; Sang Hoon Lee; Moon Kyun Cho
Journal:  Lasers Med Sci       Date:  2020-06-23       Impact factor: 3.161

Review 2.  The use of lasers in vitiligo, an overview.

Authors:  N F Post; N Ezekwe; V S Narayan; M W Bekkenk; N Van Geel; I Hamzavi; T Passeron; A Wolkerstorfer
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-03-01       Impact factor: 9.228

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.